

MDxHealth SA

**Limited Liability Company
(société anonyme)**

CAP Business Center
Zone Industrielle des Hauts-Sarts
Rue d'Abhoos 31
4040 Herstal, Belgium
VAT BE 0479.292.440 (RLP Liège, Division Liège)

**INVITATION
SPECIAL AND EXTRAORDINARY GENERAL MEETINGS**
to be held on Thursday, 30 July 2020, at 1:00 p.m.

The holders of securities issued by MDxHealth SA (the "**Company**") are invited to a special general shareholders' meeting of the Company. After the agenda of the special general shareholders' meeting has been treated, the meeting will be shortly suspended in order to be continued as an extraordinary general shareholders' meeting before a notary public.

GENERAL INFORMATION

Date, hour and venue: The special and extraordinary general shareholders' meetings will be held on Thursday, 30 July 2020 at 1:00 p.m. at the offices of notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time. There is no attendance quorum requirement for the special general shareholders' meeting. As the quorum required for the deliberation and voting on the items on the agenda of the extraordinary general shareholders' meeting held on 28 May 2020 was not reached, there is also no attendance quorum requirement for the extraordinary general shareholders' meeting.

Closed doors: Exceptionally, and in accordance with the Belgian Royal Decree no. 4 of 9 April 2020 on miscellaneous provisions relating to co-ownership and corporate and association law in the context of the fight against the COVID-19 pandemic (the "**Belgian Royal Decree no. 4**"), the Board of Directors of the Company has decided to hold the special and extraordinary general shareholders' meetings behind closed doors without the physical presence of the holders of securities of the Company and their representatives. This has been decided in order to allow the Company to ensure that the measures against the spread of the COVID-19 pandemic that could still be in force at the time of the general shareholders' meeting can be respected, and are in the interest of the health of individual holders of securities, as well as of the Company's employees and others in charge of the organisation of the general shareholders' meetings. As a result, the shareholders of the Company can exercise their voting rights only by voting by mail or by means of a written proxy to the Chairman of the Board of Directors. Furthermore, holders of securities of the Company can only exercise their right to ask questions related to the items on the respective agendas of the special and extraordinary general shareholders' meetings by means of written questions prior to the respective meetings. For more information regarding the voting by mail, the attendance by means of a written proxy, and the exercise of the right to ask questions, please see below under "—Participation to the meetings".

SPECIAL GENERAL MEETING

Agenda and proposed resolutions: The agenda and proposed resolutions of the special general shareholders' meeting of the Company which, as the case may be, can be amended at the meeting on behalf of the Board of Directors, are as follows:

1. Appointment of Dr. Regine Slagmulder as independent director

Taking into account the recommendation of the Nomination and Remuneration Committee, the Board of Directors recommends that Regine Slagmulder BV, represented by Dr. Regine Slagmulder as permanent representative, be appointed as Independent Director of the Company for a term of three years.

Dr. Regine Slagmulder is a partner and full professor in management accounting & control at Vlerick Business School. Previously, she worked as a strategy practice consultant at McKinsey & Company. She also previously worked as a professor of management accounting at INSEAD and at the University of Tilburg. Dr. Regine Slagmulder graduated in civil electrotechnical engineering and industrial management from the University of Ghent, after which she took a management doctorate at Vlerick Business School. As part of her research activities, she was a research fellow attached to INSEAD, Boston University (USA) and the P. Drucker Graduate Management Center at Claremont University (USA). Her research and teaching work lies within the area of performance, risk and governance.

Based on information made available by Regine Slagmulder BV, represented by Dr. Regine Slagmulder as permanent representative, it appears that each of Regine Slagmulder BV and Dr. Regine Slagmulder satisfies the applicable requirements in order to be nominated as Independent Directors in accordance with article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code.

Proposed resolution: The general shareholders' meeting resolves to appoint Regine Slagmulder BV, represented by Dr. Regine Slagmulder as permanent representative, as Independent Director of the Company within the meaning of article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code, for a term of three years, up to and including the closing of the annual general shareholders' meeting to be held in 2023 which will have decided upon the financial statements for the financial year ended on 31 December 2022.

2. Appointment of Dr. Eric Bednarski as director

On 24 April 2020, the Company and MVM V LP and MVM GP (No.5) LP (together "MVM") entered into a subscription agreement pursuant to which, amongst other things, MVM agreed to subscribe for 20,162,924 new shares of the Company. The new shares were issued by the Company on 15 May 2020. Within the context of the subscription agreement, the Company agreed to propose to the Company's general shareholders' meeting to appoint Dr. Eric Bednarski, one of the partners of MVM and currently an observer to the Company's board of directors, as director of the Company. In view hereof, and taking into account the recommendation of the Nomination and Remuneration Committee, the Board of Directors recommends that Dr. Eric Bednarski be appointed as Director of the Company for a term of three years.

Dr. Eric Bednarski is a partner of MVM, and joined MVM in 2008. Before joining MVM, he was a partner at Advent Healthcare Ventures and a principal at Advent International Corporation. Prior to advent, he was a director in the Corporate Finance Group of Silicon Valley Bank. Dr. Eric Bednarski has a B.S. degree in Neural Science from Brown University and a Ph.D. in Biological Sciences from the University of California, Irvine.

Proposed resolution: The general shareholders' meeting resolves to appoint Dr. Eric Bednarski as Director of the Company for a term of three years, up to and including the closing of the annual general shareholders' meeting to be held in 2023 which will have decided upon the financial statements for the financial year ended on 31 December 2022.

Note: If the proposed resolutions set out in points 1 and 2 are approved by the general shareholders' meeting, the Company's Board of Directors will be composed of (1) Mr. Michael K. McGarrity, Chief Executive Officer (CEO), Executive Director and Managing Director (until 2023), (2) Ahok BV, represented by Mr. Koen Hoffman, Independent Director and Chairman of the Board of Directors (until 2021), (3) TSTILL ENTERPRISES LLC, represented by Timothy Still, Independent Director (until 2023), (4) Hilde Windels BV, represented by Ms. Hilde Windels, Independent Director (until 2023), (5) Qaly-Co BV, represented by Dr. Lieve Verplancke, Independent Director (until 2021), (6) Gengest BV, represented by Mr. Rudi Mariën, Non-Executive Director (until 2021), (7) Valiance Advisors LLP, represented by Mr. Jan Pensaert, Non-Executive Director (until 2021), (8) Regine Slagmulder BV, represented by Dr. Regine Slagmulder, Independent Director (until 2023), and (9) Dr. Eric Bednarski, Non-Executive Director (until 2023).

3. Remuneration of the directors

Taking into account the recommendation of the Nomination and Remuneration Committee, the Board of Directors proposes that the remuneration of the members of the Board of Directors be amended as set out in the proposal resolution.

Proposed resolution: The remuneration of the members of the board of directors of the Company shall be as follows:

- (a) The mandate of the non-executive directors of the Company shall be remunerated as follows:
 - (i) Each non-executive director shall be entitled to a maximum annual fixed remuneration of EUR 35,000.00 (ca. USD 40,000).
 - (ii) The chairperson of the Board of Directors shall be entitled to an additional maximum annual fixed remuneration of EUR 31,000.00 (ca. USD 35,000).
 - (iii) The chairperson of the Audit Committee shall be entitled to an additional maximum annual fixed remuneration of EUR 17,500.00 (ca. USD 20,000), and the other members of the Audit Committee (other than the chairperson of this committee) shall be entitled to an additional maximum annual fixed remuneration of EUR 9,000.00 (ca. USD 10,000).
 - (iv) The chairperson of the Nomination and Remuneration Committee shall be entitled to an additional maximum annual fixed remuneration of EUR 17,500.00 (ca. USD 20,000), and the other members of the Nomination and Remuneration Committee (other than the chairperson of this committee) shall be entitled to an additional maximum annual fixed remuneration of EUR 5,500.00 (ca. USD 6,000).
 - (v) The remuneration set out in paragraphs (ii), (iii) and (iv) shall be in addition to the remuneration set out in paragraph (i) and can be combined, depending on whether the eligibility criteria set out in these paragraphs have been met. The remuneration can be reduced *pro rata temporis* depending on the duration of the mandate, chairpersonship or membership of a director during a given year. All amounts are exclusive of VAT and similar charges.
- (b) Notwithstanding the foregoing, non-executive directors that are not independent directors shall not be entitled to a remuneration in cash as set out in paragraph (a), but shall each year be entitled to receive share options for a maximum of 10,000 shares of the Company.
- (c) The rules set out in paragraphs (a) and (b) shall apply as from 1 July 2020, whereby the remuneration for the period from 1 July until 31 December 2020 shall be 50% of the remuneration referred to in paragraphs (a) and (b).

No attendance quorum: There is no attendance quorum requirement for the deliberation and voting on the respective items referred to in the aforementioned agenda of the special general shareholders' meeting.

Voting and majority: Subject to applicable legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolutions referred to in the aforementioned agenda of the special general shareholders' meeting shall be passed if they are approved by a simple majority of the votes validly cast by the shareholders. Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to participate to the special general shareholders' meeting, but only with an advisory vote.

EXTRAORDINARY GENERAL MEETING

Agenda and proposed resolution: The agenda and proposed resolution of the extraordinary general shareholders' meeting of the Company which, as the case may be, can be amended at the meeting on behalf of the Board of Directors, are as follows:

1. Submission of the special report of the Board of Directors in accordance with article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the authorised capital

Consideration, discussion and submission of the special report of the Board of Directors in accordance with article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the powers granted to the Board of Directors under the authorised capital, as set out below in item 2 of the agenda of the extraordinary general shareholders' meeting, and setting out the specific circumstances in which the Board of Directors will be able to use its powers under the authorised capital, and the purposes that it should pursue.

2. Renewal of the authorisation to the Board of Directors to increase the share capital within the framework of the authorised capital

In order to allow the Board of Directors the flexibility to raise additional equity based financing as and when the need may arise or an opportunity would present itself, the Board of Directors proposes that it be granted limited powers under the authorised capital to increase the Company's share capital by a maximum amount of 100% during a term of 5 years, all as further set out below. For further information on the circumstances in which the Board of Directors could make use of the authorised capital and the objectives that the Board of Directors would pursue with the authorised capital, see also the special report referred to in item 1 of the agenda of the extraordinary general shareholders' meeting.

Proposed resolution: The general shareholders' meeting resolves to renew the authorisation to the Board of Directors to increase the share capital in one or several times, during a period of five (5) years as from the publication in the Annexes to the Belgian Official Gazette of this authorisation, with an aggregate amount equal to up to 100% of the amount of the share capital of the Company, and this in accordance with the terms and conditions set forth in the special report of the Board of Directors prepared in accordance with article 7:199 of the Belgian Companies and Associations Code, as referred to in agenda item 1 of this extraordinary general shareholders' meeting. Consequently, the general shareholders' meeting resolves to delete article 6 "Authorised capital" of the articles of association of the Company entirely and to replace it with the following text (whereby the date referred to in the sub-section between square brackets shall be the date of the general shareholders' meeting approving the renewed authorised capital, and the amount referred to in the sub-section between brackets shall be the amount of the Company's share capital at the time of the general shareholders' meeting approving the authorised capital):

"Article 6: Authorised capital

The board of directors is authorised to increase the share capital of the company on one or several occasions by a maximum aggregate amount of [100% of the company's share capital at the time of the adoption of the new authorised capital].

The board of directors may increase the share capital by contributions in cash or in kind, by capitalisation of reserves, whether available or unavailable for distribution, and capitalisation of issue premiums, with or without the issuance of new shares, with or without voting rights, that will have the rights as will be determined by the board of directors. The board of directors is also authorised to use this authorisation for the issuance of convertible bonds or subscription rights, bonds with subscription rights or other securities.

This authorisation is valid for a period of five years as from the date of publication in the Annexes to the Belgian Official Gazette of an extract of the minutes of the extraordinary general shareholders' meeting of the company held on [May 28, 2020].

In the event of a capital increase decided by the board of directors within the framework of the authorised capital, all issue premiums booked, if any, will be accounted for in accordance with the provisions of these articles of association.

The board of directors is authorised, when exercising its powers within the framework of the authorised capital, to restrict or cancel, in the interest of the company, the preferential subscription rights of the shareholders. This restriction or cancellation of the preferential subscription rights can also be done in favour of members of the personnel of the company or of its subsidiaries, or in favour of one or more persons other than members of the personnel of the company or of its subsidiaries.

The board of directors is authorised, with the right of substitution, to amend the articles of association, after each capital increase that has occurred within the framework of the authorised capital, in order to bring them in conformity with the new situation of the share capital and the shares."

3. Amendment and restatement of the articles of association of the Company to bring these in line with the Belgian Companies and Associations Code

Proposed resolution: The general shareholders' meeting resolves to amend and restate the articles of association of the Company in accordance with the proposed draft of the articles of association that is attached to the explanatory note that has been prepared by the Board of Directors pursuant to article 7:129, §3, 4° of the Belgian Companies and Associations Code and which is available on the Company's website, with a view to:

- (a) bringing the articles of association in line with the provisions and requirements of the Belgian Companies and Associations Code of 23 March 2019 in accordance with article 39, §1, third paragraph of the Belgian Act of 23 March 2019 regarding the introduction of the Belgian Companies and Associations Code and regarding various provisions, which for example applies to (i) the proposed amendments to article 2 in relation to the registered office of the Company, (ii) several proposed amendments to update references to the (former) Belgian Companies Code to the (new) Belgian Companies and Associations Code (see articles 4, 6, 7, 13, 15, 18, 21, 28, 31, 36, 46, 47 and 50), (iii) several proposed amendments order to reflect the new terms and concepts of the Belgian Code of Companies of Associations (such as in articles 1, 3, 5, 6, 7, 9, 10, 11, 18, 23, 30, 32, 33, 38, 45, 51) and (iv) the proposed application of the model of monistic governance and the removal of the possibility to put in place an executive committee (such as in articles 17, 25, 26 and 27);
- (b) making some technical changes in the articles of associations (such as in articles 7, 8, 9, 13, 14, 18, 19, 20, 23, 24, 25, 31, 35, 37, 39, 40, 41, 48 and 49).

Quorum: As this extraordinary general shareholders' meeting constitutes the second extraordinary general shareholders' meeting for the aforementioned agenda items, no quorum is required for the deliberation and voting on the items referred to in the aforementioned agenda.

Voting and majority: Subject to applicable legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolutions referred to in the aforementioned agenda of the extraordinary general shareholders' meeting shall be passed if they are approved by a majority of 75% of the votes validly cast by the shareholders. Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to participate to the extraordinary general shareholders' meeting, but only with an advisory vote.

PARTICIPATION TO THE MEETINGS

Introduction: Holders of securities issued by the Company who wish to participate to the special and extraordinary general shareholders' meetings of the Company should take into account the formalities and procedures described below.

Registration date: The registration date for the special and extraordinary general shareholders' meetings shall be Thursday 16 July 2020, at midnight (12:00 a.m., Belgian time). Only persons owning securities issued by the Company on Thursday 16 July 2020, at midnight (12:00 a.m., Belgian time) shall be entitled to participate to, and, as the case may be, vote at the special and extraordinary general shareholders' meetings. Only shareholders are entitled to vote. The holders of subscription rights can participate to the special and extraordinary general shareholders' meetings but only with an advisory vote. Shareholders, as well as holders of subscription rights must satisfy the formalities that are described under "—Participation to the meetings".

Participation to the meetings: In order to be able to participate to the special and extraordinary general meetings, a holder of securities issued by the Company must satisfy two conditions: (a) be registered as holder of such securities on the registration date, and (b) notify the Company, as described below:

- (a) *Registration:* Firstly, the right for a holder of securities issued by the Company to participate to and, as applicable, to vote at the special and extraordinary general shareholders' meetings is only granted on the basis of the registration of the securities concerned on the aforementioned registration date at midnight, via registration, in the applicable register book for the securities concerned (for registered

securities) or in the accounts of a certified account holder or relevant settlement institution for the securities concerned (for dematerialised shares).

- (b) *Notification:* Secondly, in order to participate to the special and extraordinary general shareholders' meetings, the holders of securities issued by the Company must notify the Company or ING Belgium whether they want to participate to the meetings and must do so prior to or at the latest on Sunday, 26 July 2020, by sending the signed voting by mail form or signed proxy. The signed voting by mail form or signed proxy must reach the Company at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d'Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Jean-Michaël Scelso) or by e-mail at agsm@mdxhealth.com, at the latest on the fourth calendar day prior to the special and extraordinary general shareholders' meeting, i.e., on or before Sunday, 26 July 2020 at the latest. The signed voting by mail form or signed proxy can be delivered by the aforementioned date with all possible means, including by means of an e-mail with a scanned or photographed copy of the signed voting by mail form or signed proxy. The notification to ING Belgium can be made at the counters of ING Belgium on or before Friday, 24 July 2020 at the latest. For the holders of dematerialised securities, the notification should include a certificate confirming the number of securities that have been registered in their name on the registration date. The certificate can be obtained by the holders of the dematerialised securities with the certified account holder, the applicable settlement institution, or the relevant financial intermediary for the securities concerned.

Voting by mail: The shareholders can vote by mail in accordance with article 42bis of the Company's articles of association and article 6, §1 of the Belgian Royal Decree no. 4. Votes by mail must be cast by means of the form prepared by the Company. The voting by mail form can be obtained on the Company's website (<http://www.mdxhealth.com>). The voting by mail form must be signed in writing or electronically. The electronic signature must be a qualified electronic signature in the sense of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended, or an electronic signature that complies with the conditions set out in article 1322 of the Belgian Civil Code. Signed voting by mail form must reach the Company by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d'Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Jean-Michaël Scelso) or by e-mail accompanied by a scanned or photographed copy of the voting by mail form at agsm@mdxhealth.com, at the latest on the fourth calendar day prior to the special and extraordinary general shareholders' meeting, i.e., on or before Sunday, 26 July 2020 at the latest. Holders of securities who wish to vote by mail must in any case comply with the formalities to participate to the meeting as explained under "—Participation to the meetings".

Representation by proxy: In accordance with article 6, §1 and §2 of the Belgian Royal Decree no. 4, the holders of securities can participate to the meetings and vote, as applicable, through a written proxy to the Chairman of the Board of Directors. The written proxy must contain specific voting instructions for each proposed resolution. Proxy forms can be obtained on the Company's website (<http://www.mdxhealth.com>). The proxy must be signed in writing or electronically. The electronic signature must meet the same requirements as the electronic signature for the voting by mail form (see also "—Voting by mail"). Signed proxies must reach the Company by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d'Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Jean-Michaël Scelso) or by e-mail accompanied by a scanned or photographed copy of the proxy form at agsm@mdxhealth.com, at the latest on the fourth calendar day prior to the special and extraordinary general shareholders' meeting, i.e., on or before Sunday, 26 July 2020 at the latest. Holders of securities who wish to be represented by proxy must, in any case comply with the formalities to participate to the meetings, as explained under "—Participation to the meetings".

Amendments to the agenda and additional proposed resolutions in relation to the special general shareholders' meeting: Shareholders who alone or together with other shareholders hold at least 3% of the share capital of the Company have the right to put additional items on the agenda of the special general shareholders' meeting and to table draft resolutions in relation to items that have been or are to be included in the agenda of the special general shareholders' meeting. This right does not apply in relation to the agenda of the extraordinary general shareholders' meeting. Shareholders that wish to exercise this right must prove on the date of their request that they own at least 3% of the outstanding shares. The ownership must be based, for dematerialised shares, on a certificate issued by the applicable settlement institution for the securities concerned, or by a certified account holder, confirming the number of securities that have been registered in the name of the relevant shareholders, and, for registered shares, on a certificate of registration of the relevant shares in the share register book of the Company. In addition, the shareholders concerned must, in any case, comply with the

formalities to participate to the special general shareholders' meeting, as explained under "—Participation to the meetings", with at least 3% of the outstanding shares. A request to put additional items on the agenda and/or to table draft resolutions must be submitted in writing, and must contain, in the event of an additional agenda item, the text of the agenda item concerned and, in the event of a draft resolution, the text of the draft resolution. The request must also mention the mail or e-mail address to which the Company will send the confirmation of receipt of the request. The request must reach the Company by mail at its registered office (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d'Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Jean-Michaël Scelso) or by e-mail at agsm@mdxhealth.com at the latest on the twenty-second calendar day prior to the special and extraordinary general shareholders' meetings, i.e., on or before Wednesday, 8 July 2020 at the latest. In case of amendments to the agenda and proposed additional resolutions as aforementioned, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional draft resolutions no later than on the fifteenth calendar day prior to the special and extraordinary general shareholders' meetings, i.e., on or before Wednesday, 15 July 2020 at the latest. In addition, the Company shall make amended forms available for votes by proxy. Proxies that reach the Company prior to the publication of an amended agenda remain valid for the agenda items to which the proxies apply, subject, however, to applicable law and the further clarifications set out on the proxy forms.

Right to ask questions: Each holder of securities issued by the Company has the right to ask questions to the Directors and the Statutory Auditor related to items on the agenda of a general shareholders' meeting. In accordance with article 6, §3 of the Belgian Royal Decree no. 4, questions can only be submitted in writing prior to the meetings. Written questions must reach the Company by mail at its registered office (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d'Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Jean-Michaël Scelso) or by e-mail at agsm@mdxhealth.com at the latest on the fourth calendar day prior to the special and extraordinary general shareholders' meetings, i.e., on or before Sunday, 26 July 2020 at the latest. Answers to such written questions will be provided in writing and will be published on the Company's website (<http://www.mdxhealth.com>) on or before Thursday, 30 July 2020 at the latest, but before the vote on items on the respective agendas of the meetings concerned in accordance with applicable law. In addition, in order for written questions to be considered, the holders of securities issued by the Company who submitted the written questions concerned must comply with the formalities to participate to the meetings, as explained under "—Participation to the meetings" and under "—Voting by mail" or "—Representation by proxy".

Recommendation to use e-mail: As postal services could be disrupted and as the deadline for the submission of voting by mail forms, proxies and written questions is a Sunday during which there is usually no ordinary postal service, the Company recommends the holders of its securities to use e-mail for all communication with the Company regarding the general shareholders' meetings. The Company's e-mail address for such communication is: agsm@mdxhealth.com. The Company also points at that all (updated) forms and other documentation in relation to the general shareholders' meetings will not be physically available at the Company's registered office and will not be distributed by mail, but will be available on the Company's website (<http://www.mdxhealth.com>). See also "—Available documentation".

DATA PROTECTION

The Company is responsible for the processing of personal data it receives from, or collects about, holders of securities issued by the Company and proxy holders in the context of general shareholders' meetings. The processing of such data will be carried out for the purposes of the organisation and conduct of the relevant general shareholders' meeting, including the convening notices, registrations, participation and voting, as well as for maintaining lists or registers of security holders, and the analysis of the investor and security holder base of the Company. The data include, amongst others, identification data, the number and nature of securities of a holder of securities issued by the Company, proxies and voting instructions. This data may also be transferred to third parties for the purposes of assistance or services to the Company in connection with the foregoing. The processing of such data will be carried out, mutatis mutandis, in accordance with the Company's Privacy Policy, available on the Company's website (<https://mdxhealth.com/privacy-policy>). The Company draws the attention of the holders of securities issued by the Company and proxy holders to the description of the rights they may have as data subjects, such as, among others, the right to access, the right to rectify and the right to object to processing, which are outlined in the section 'Information regarding your rights' of the aforementioned Privacy Policy. All this does not affect the rules that apply in connection with the registration and participation to the general shareholders' meeting. To exercise rights as a data subject and for all other information regarding the processing of personal data by or on behalf of the Company, the Company can be contacted by e-mail at dataprotection@mdxhealth.com.

AVAILABLE DOCUMENTATION

The following documentation is available on the Company's website (<http://www.mdxhealth.com>): the notice convening the special and extraordinary general shareholders' meetings, an explanatory note regarding the agenda and proposed resolutions or, if no resolutions are proposed, a commentary by the Board of Directors, updates of the agenda and proposed resolutions, in case of amendments to the agenda and proposed resolutions, the documents to be submitted to the special and extraordinary general shareholders' meetings as referred to in the agenda of the meetings, the voting by mail form, and the proxy form.

Please address any correspondence on this matter to MDxHealth SA, Mr. Jean-Michaël Scelso, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d'Abhooz 31, 4040 Herstal, Belgium. The facsimile number is +32 (0)4 259 78 75 and the e-mail address is agsm@mdxhealth.com.

On behalf of the Board of Directors

THIS DOCUMENT IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SHARES OR OTHER SECURITIES OF MDXHEALTH SA. THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL.